53 results about "Heparin.low molecular weight" patented technology

The invention relates to biotinylated low molecular weight heparins comprising constituent polysaccharides having at their reducing ends at least one covalent bond with biotin or a biotin derivative, and also to the process for preparing them, to pharmaceutical compositions containing them and to their therapeutic use.

The invention relates to a preparation and purification method of a carbohydrate library containing N-acetylated heparin. The method comprises the following steps: enriching oligosaccharide containing an N-acetylated structure through deep enzymolysis of low molecular weight heparin with heparinase I, then, preparing a series of heparin oligosaccharide crude samples ranging from disaccharide to tetradecasaccharide by Bio-Gel P10 gel chromatography, further separating the crude samples by means of strong anion high performance liquid chromatography and other methods, and respectively purifying the crude samples to obtain four hexasaccharide segments and three octasaccharide fragments; analyzing the disaccharide constituent of each purified oligosaccharide by compound enzymolysis with heparinase I, heparinase II and heparinase III and strong anion chromatography, and primarily deducing sequence structures of the four hexasaccharide and the three octasaccharide in combination with heparinase I substrate specificity; and finally, identifying the structure by electrospray ionization-ion trap-time of flight mass spectrometry (ESI-IT-TOF-MS). The preparation method provided by the invention can be used for solving the problem of difficulty in preparation and structure determination of oligosaccharide containing N-acetylated heparin, which makes research on a relationship between a special structure and functions of heparin/heparan sulfate developed further.

The invention relates to a detection method for detecting the anti-Xa potency of heparin (salt) or heparin (salt) with the low molecular weight through a coagulometer. The method comprises the following steps of 1 standard serial solution preparing; 2 standard curve drawing; 3 sample processing and detecting; 4 calculating. According to the method, four kinds of standard solution concentrations are achieved through automatic diluting performed with the coagulometer, personal errors are few, all the operation steps are automatically completed, the man-made influences of the time, the temperature and stirring are completely eradicated, and the experiment precision is high; reaction of the used reagents is changed from semimicro reaction to micro reaction, and therefore the expensive reagents are saved; a linear equation method is adopted and is intuitional.

The invention discloses a heparin lyase mutant and a recombinant expression method thereof, and belongs to the technical field of bioengineering. The heparin lyase III provided by the invention has higher catalytic efficiency and thermal stability, the catalytic efficiency of the mutant S264F/Y490K/D321N is improved by 1.68 times compared with that of an original strain, and preparation of low-molecular-weight heparin is facilitated. Heparin lyase III from bacteroides thetaiotaomicron is subjected to heterologous recombination expression, and the intracellular enzyme activity can reach 4000 U/L or above.

The invention provides an accurate, economical, automatable, high throughput method for the determination of the concentration of glycosaminoglycan anticoagulants, including low molecular weight heparin (LMWH) anticoagulants, in aqueous solutions. A method for cleaning a unit of manufacturing equipment used in the preparation of a LMWH to obtain an acceptable residual concentration of LMWH is further provided.

The invention discloses a preparation method of submicron order core/shell structure poly(lactic-co-glycolic) microsphere with a uniform particle size. The microsphere is of a core/shell structure, the particle size is 400-600nm, and the average shell thickness is 70nm. The preparation process comprises the following steps of: dissolving bovine serum albumin, carboxymethyl chitosan or low molecular weight heparin into a phosphate buffer liquid to be used as solution 1; dissolving PLGA and a emulsifier F127 into dichloromethane to be used as a solution 2; conducting ultrasonic dispersion on the solution 1 and the solution 2 so as to form a primary emulsion; further dropping the primary emulsion into a calcium chloride solution, and conducting ultrasonic dispersion in an ice bath so as to form a composite emulsion; and volatilizing the solvent, dialyzing, centrifugally washing, freezing and drying so as to obtain the PLGA microsphere. The preparation method has the advantages that the preparation process is simple, and meanwhile due to the core/shell structure of the microsphere, medicines can be wrapped into the core, the particle size is uniform, the medicine release action can be predicted, and the microsphere is convenient to be compounded with a tissue engineering bracket.

The invention relates to a preparation and purification method of heparin hexasaccharides containing (i)N(i)-unsubstituted glucosamine (GlcNH3+). The preparation and purification method comprises the following steps: using enzymolysis low molecular weight heparin as the raw material, separating and purifying the heparin sodium hexasaccharide by methods of gel chromatography and ion exchange HPLC; preparing heparin pyridine hexasaccharide by using cation exchange resin and pyridine neutralization process; finally preparing heparin hexasaccharides with different numbers of GlcNH3+ by the (i)N(/i)-sulfate removal method, and separating and purifying the heparin hexasaccharide by the SAX-HPLC method. The preparation and purification method can specifically prepare the heparin oligosaccharides containing different numbers and sequences of GlcNH3+, and provide important oligosaccharides libraries for researching the structure and function of the GlcNH3+ residues in the heparin sulfate and the relationship between the GlcNH3+ residues and diseases.

The invention relates to the field of pharmaceutical preparations, and relates to a calcium phosphate-lipid nano-drug co-delivery system consisting of low molecular weight heparin and a prodrug of a natural drug and a preparation method for the nano-drug co-delivery system. According to the nano-drug co-delivery system, nanoparticles prepared from a biodegradable lipid material are taken as carriers, and the phosphorylated prodrug PIC-POOH of the natural drug piceatannol (PIC) is physically entrapped, and the low molecular weight heparin (LMWH) adsorbs on the outer layers of the carriers by static electricity; and a nano preparation concentrates at a tumor site by utilizing the long circulating performance of the nano preparation and the enhanced permeability and retention (EPR) effect ofa solid tumor tissue, a related pathway for tumor cell metastasis is then regulated, angiogenesis is inhibited, and the anti-tumor metastasis action is exerted. Proved by assays, the nano-drug co-delivery system can inhibit the epithelial-mesenchymal transition (EMT) progress of tumor cells; proved by a tube formation assay, the nano-drug co-delivery system can significantly inhibit tumor angiogenesis; proved by in vivo administration evaluation, the nano-drug co-delivery system can reduce formation of lung metastasis on a mice model, and prolongs the survival time of tumor-bearing mice; and the nano-drug co-delivery system has an obvious anti-tumor metastasis effect, especially reduces triple negative breast cancer metastasis, and has high safety.

The invention belongs to the technical field of pharmaceutical preparations, particularly relates to a low-molecular weight heparin calcium raw material medicine and a preparation thereof, and aims at providing low-molecular weight heparin calcium and a low-molecular weight heparin calcium product to overcome the defects of the prior art. The raw material medicine is prepared by the processes of acid resin acidification, sodium nitrite pyrolysis, calcium oxide neutralization, anhydrous calcium chloride ethanol solution alcohol precipitation, and filtering and drying. Particularly, nitrous acid pyrolysis with relatively low pH area and relatively high dose is achieved in the presence of ethanol with a certain concentration range, the low-molecular weight heparin calcium preparation up to the standard is prepared, and a safe, effective, safe and quality-controlled low-molecular weight heparin calcium preparation is finally provided.

The invention discloses a production and purification process of high-purity low-molecular-weight heparin sodium, and the proocess comprises the following steps of: S1, weighing 80-120g of crude heparin sodium, performing dissolving with purified water, controlling the temperature of the solution to be below 30DEG C, and conducting stirring for dissolving to prepare a 10%-20% (w/v) crude heparin sodium solution; S2, adding the crude heparin sodium solution in a NaCl solution with a concentration of 2% to prepare a 5%-10% (w/v) crude heparin sodium solution, adding alkaline protease, and carrying out heat preservation enzymolysis at 35-50DEG C for 3-6h to obtain an enzymatic hydrolysate; and S3, carrying out centrifugal separation on the enzymatic hydrolysate obtained in S2 to obtain a supernatant and a precipitate, and discarding insoluble impurities. According to the method, macromolecular substances such as residual protein in the produced low-molecular-weight heparin are interceptedby using an ultrafiltration method, so that the safety of the low-molecular-weight heparin is improved, and the low-molecular-weight heparin sodium is low in protein content, high in purity and highin yield.

The invention belongs to the field of preparation of low-molecular-weight heparin, and relates to a method for preparing nadroparin calcium and dalteparin sodium. Specifically, the invention relates to a method for preparing low-molecular-weight heparin, which comprises the steps of heparin sodium cracking, reduction, neutralization and ultrafiltration in a microchannel reactor, and the low-molecular-weight heparin is selected from nadroparin calcium and dalteparin sodium. According to the method, the selectivity of heparin sodium cracking reaction is improved, and the probability of repeated cracking is reduced, so that the increase of micromolecular heparin is avoided, the load of later ultrafiltration molecular weight screening is reduced, and the yield of the product is improved.

The invention discloses fusion expression of heparin lyase in bacillus subtilis and application of heparin lyase, and belongs to the technical field of bioengineering. According to the invention, bacillus subtilis is used as a host for heterologous expression of heparin lyase I from Bacteroides thetaiotaomicron, an oligopeptide sequence, an optimized promoter and a 5'UTR sequence are fused at an N terminal, a gene FhepIII of heparin lyase III is connected to a C terminal of a BhepI gene by using a GGGS oligopeptide, a fusion enzyme BhepI-FhepIII is constructed, and through comparison of heparin sodium splitting capacities of the BhepI and the FhepIII, it is found that the molecular weight of heparin obtained by the fusion enzyme can be as low as 1300Da or below, and the heparin lyase has stronger anticoagulant activity, and lays a foundation for industrial production of the heparin lyase in bacillus subtilis and preparation of low-molecular-weight heparin.

The invention discloses a camptothecin prodrug as well as a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations. According to the invention, a prodrug strategy is utilized, camptothecin is chemically bonded to a low molecular weight heparin (LMWH) molecular chain to form a prodrug, and the synthesized LMWH-CPT is self-assembled to form the nanoparticles by virtue of the hydrophobicity of the camptothecin and the hydrophilicity of the low molecular weight heparin. The camptothecin prodrug LMWH-CPT not only has the advantages of a polymer prodrug, but also the equilibrium constant pKa of camptothecin molecules in a nanoparticle core is remarkably increased by virtue of the unique hydrophobic interaction of the camptothecin molecules, so that the camptothecin prodrug LMWH-CPT is ensured to have a relatively high closed-loop rate after being stored in a neutral environment and being subjected to injection administration.

The invention belongs to the technical field of biological medicine, and particularly relates to a method for removing bacterial endotoxin in low-molecular-weight heparin. According to the method for removing the bacterial endotoxin in the low-molecular-weight heparin, the bacterial endotoxin is removed through an n-butyl alcohol-butyl acetate extraction method, after extraction is completed, purified water is supplemented for equal-volume ultrafiltration, and a residual solvent can be effectively removed. The method for removing bacterial endotoxin in low-molecular-weight heparin provided by the invention has the characteristics of simplicity, convenience, rapidness, thorough endotoxin removal, small product loss, easiness in production amplification and the like, and the quality of a final product meets EP standard requirements.